Trial data underpins FDA approval of omalizumab for food allergy

Today's Food and Drug Administration approval of a supplemental biologics license for the monoclonal antibody omalizumab (Xolair) highlights the vital role of the National Institutes of Health-supported research that underpins ...


Ligelizumab safely, effectively treats hives

(HealthDay)—Ligelizumab appears to be a safe and effective treatment option for chronic spontaneous urticaria, according to a study published in the Oct. 3 issue of the New England Journal of Medicine.

Diseases, Conditions, Syndromes

Omalizumab effective for chronic spontaneous urticaria

(HealthDay)—Omalizumab, alone or in combination with a short-term course of corticosteroids, is highly effective for the treatment of refractory chronic spontaneous urticaria (CSU), according to a study published online ...


Intranasal omalizumab does not increase serum IgE levels

(HealthDay)—In patients with birch pollen allergy, intranasal administration of omalizumab does not result in relevant change of allergen-specific and total immunoglobulin E (IgE) levels, according to a pilot study published ...

Diseases, Conditions, Syndromes

A step forward in the treatment of chronic urticaria

An international study involving dermatologists from the Hospital del Mar and Spanish subjects has concluded that a drug normally used to treat severe bronchial asthma caused by allergies (Omalizumab) rapidly eliminates the ...

page 1 from 2